Clinical Trials Logo

Filter by:
NCT ID: NCT05376761 Recruiting - Clinical trials for PD - Parkinson's Disease

EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease

Start date: May 31, 2022
Phase: Phase 4
Study type: Interventional

Dexmedetomidine (DEX) sedation is widely used in deep brain stimulation implantation (DBSI) of patients With Parkinson's disease. However, intraoperative application of DEX may affect the discharge activity of deep brain nuclei and reduce the discharge frequency of Subthalamic nucleus (STN) neurons. At present, there is still a lack of prospective intervention research to explore the optimal dose that does not affect MER mapping in patients with Parkinson's disease. The present study uses the Dixon and Massey up-and-down method to analyze the EC50 of DEX in patients with PD undergoing STN-DBS sedation, to clarify the balance meets the sufficient comfort of patients without affecting the accurate target of MER and the optimal dosage of DEX for boundary recognition.

NCT ID: NCT05376722 Recruiting - Neoadjuvant Therapy Clinical Trials

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Start date: February 22, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy

NCT ID: NCT05376345 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.

NCT ID: NCT05376124 Recruiting - Clinical trials for Hepatitis B, Chronic

Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory

Start date: January 1, 2022
Phase:
Study type: Observational

Refractory hepatitis B is to point to although standard application nucleoside (acid) analogue treatment undertakes primary treatment and two strengthen treatment, but existence is persistent viremia. Currently, there is no consensus on salvage therapy for patients who remain virus-positive after a second round of antiviral therapy. This is the first multicenter, prospective, parallel controlled, open-label cohort study to compare the efficacy and safety of TDF/TAF combined with ETV1.0mg regimen versus continuation of the original regimen in the treatment of refractory hepatitis B.

NCT ID: NCT05376111 Recruiting - Clinical trials for T-cell Acute Lymphoblastic Leukemia

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.

NCT ID: NCT05376098 Recruiting - Clinical trials for Acute Ischemic Stroke

An fNIRS Study of Motor Cortical Activation in Stoke Patients

Start date: February 1, 2022
Phase:
Study type: Observational

The investigators evaluate the activation and connectivity of patients' motor regions in the acute phase of ischemic stroke by fNIRS.

NCT ID: NCT05375786 Recruiting - COVID-19 Clinical Trials

Epidemiological Study on Asymptomatic Infections and Mild Illness With Covid-19 in Shanghai

Start date: April 2, 2022
Phase:
Study type: Observational

this study is to clarify the epidemiological characteristics of Omicron variant infected persons in Shanghai, such as distribution characteristics, host and clinical characteristics, disease outcome and risk factors. especially asymptomatic infections.

NCT ID: NCT05375773 Recruiting - Clinical trials for 2019 Novel Coronavirus Infection

Povidone Iodine Nasal Irrigation and Gargling to Reduce Viral Load in Asymptomatic Patients With COVID-19

SMART-CORE
Start date: April 16, 2022
Phase: N/A
Study type: Interventional

The emergence of a novel coronavirus(SARS-CoV-2) in late 2019 has resulted in a global epidemic of the infectious condition COVID-19. Since March 2022, the Omicron mutant has caused widespread transmission in Shanghai, China, and is characterized by the majority of asymptomatic patients. Although showing no obvious symptoms, the asymptomatic patients have high transmissibility because of high viral loads in their oropharynx and nasopharynx. Therefore,this study puts forwards the hypothesis that local flushing treatment in the sino-nasal and mouth cavity can reduce the viral load to reduce their transmissibility. Nasal Irrigation and gargling is a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper respiratory tract infections. Povidone-iodine(PVP-I) is a water-soluble complex of povidone, a carrier molecule, and iodine, which has powerful microbicidal activity. Also, recent evidence of in-vitro virucidal action of povidone-iodine in Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS CoV-2) has been supported. Therefore, the study is designed to assess the virucidal effect of nasal irrigation and gargling with PVP-I against SARS-CoV-2 located in the throat. The hypothesis was that the treatment would be effective in improving the negative conversion rate of SARS-CoV-2 nucleic acid on day 10.

NCT ID: NCT05375734 Recruiting - Immunotherapy Clinical Trials

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Start date: August 17, 2021
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .

NCT ID: NCT05375721 Recruiting - Clinical trials for Postoperative Nausea and Vomiting

Prevention of PONV With Traditional Chinese Medicine

Start date: September 23, 2022
Phase: N/A
Study type: Interventional

Postoperative nausea and vomiting (PONV) is particularly one of the most common complications after laparoscopic sleeve gastrectomy (LSG). It can lead to serious adverse events and delayed activity, and prolong the time of rehabilitation and discharge. Numbers of studies have been focused on identifying risk factors and therapies of PONV. Unfortunately, there' no consistent comments for PONV prevention in women after LSG. Notably, Zusanli (ST36) acupoint and anisodamine have been evidenced to treat various gastrointestinal conditions. The primary outcome of this study was to evaluate the impact of anisodamine injection in ST36 on PONV in women following bariatric surgery.